Release date: 2 March 2011
Promoter – Financial Intermediary
Gedeon Richter Plc.
Location
Description
Financing of R&D programme for the development of new proprietary drugs and biosilimar compounds.
Objectives
Improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics, are some of the key objectives of the project. This research addresses not only an unmet medical need but also impacts the quality of life of certain patients. EIB financing of the project encourages research and technological development. In addition, the project would assist Hungary in improving its research capabilities.
Sector(s)
Proposed EIB finance (Approximate amount)
Up to EUR 150 million
Total cost (Approximate amount)
Up to EUR 382 million
Environmental aspects
R&D activities included in the project will not materially change current practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA), therefore, should not be required by the competent authorities as stated in the EU Directive 97/11 amended by Directive 2003/35.
Procurement
The promoter is a private company, not operating in the utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.
Status
Signed - 14/06/2011
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).